Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SPR | P35270 | 4/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 2/20 | 0.42 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22999576 | 0.92 | SPR (0.47) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL30421636 | 0.89 | PARP1 (0.39) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL2456754 | 0.84 | SPR (0.46) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL417157 | 0.83 | MAPT (0.45) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL21041448 | 0.82 | MAPT (0.44) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL31128509 | 0.81 | PARP1 (0.44) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL9610905 | 0.79 | MTHFD2 (0.53) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL28647996 | 0.79 | PARP1 (0.47) | MAPTSPRPARP1TNKS2PARP2 | |
| SCHEMBL415023 | 0.76 | MTHFD2 (0.52) | MAPTPARP1TNKS2PARP2MTHFD2 | |
| SCHEMBL415705 | 0.75 | MTHFD2 (0.47) | MAPTSPRMTHFD2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1607396-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1240168-B1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6800632-B2 | FOR TREATMENT OF DISORDERS MEDIATED BY GSK3 ACTIVITY, SUCH AS DIABETES, ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS, OBESITY, ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-20030008866-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-01-09 | — | — | US | disclosed |
| EP-1240168-A1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20010044436-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2001-11-22 | — | — | US | disclosed |
| WO-2001044246-A1 | BICYCLIC INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008866-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | GSK3A, GSK3B, GSKIP | MAPT 223/4885SPR 1088/4885PARP1 107/4885 |
| US-20010044436-A1 | Bicyclic inhibitors of glycogen synthase kinase 3 | GSK3A, GSK3B, GSKIP | MAPT 223/4885SPR 1088/4885PARP1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.